Polymorphisms in the promoter of the human APP gene: functional evaluation and allele frequencies in Alzheimer disease
- PMID: 12433268
- DOI: 10.1001/archneur.59.11.1793
Polymorphisms in the promoter of the human APP gene: functional evaluation and allele frequencies in Alzheimer disease
Abstract
Background: Missense mutations in the amyloid precursor protein (APP) gene cause early-onset Alzheimer disease (AD). However, little is known regarding the effects of polymorphisms in regulatory sequences of APP on AD susceptibility.
Objectives: To identify polymorphisms in the APP promoter, to test these for associations with AD, and to assess their influence on APP promoter activity in transfected cells.
Setting: Community study of 1013 people of white, African American, or Caribbean Hispanic ethnicity, 65 years and older, residing in northern Manhattan.
Main outcome measures: The diagnosis of AD was established by stringent criteria, with multiple follow-up examinations over 7 years.
Results: We identified 2 polymorphisms in the APP promoter: a rare G-->C variant at -9 and a frequent G-->C variant at +37 relative to the transcription start site. The +37C allele was most frequent in African American patients (18% frequency), followed by Caribbean Hispanic patients (10%) and white patients of European descent (3%). This allele was overrepresented among patients with AD compared with elderly controls (odds ratio [OR], 1.57; 95% confidence interval [CI], 1.08-2.27 in the combined ethnic groups), but this was not significant after adjusting for age, sex, and education (OR, 1.41; 95% CI, 0.93-2.12). A stronger association was found in participants lacking any apolipoprotein-E epsilon4 allele (OR, 2.12; 95% CI, 1.36-3.32 [univariate analysis]; OR, 2.08; 95% CI, 1.26-3.45 after adjusting for age, sex, and education). The -9C allele was not frequent enough to be evaluated for a disease association. Both variants were tested in promoter-reporter assays in U-87 glioma cells, and no differences in promoter activity were detected.
Conclusions: The -9G/C and +37G/C APP promoter polymorphisms are unlikely to contribute strongly to AD susceptibility or to cause major differences in APP expression, but the +37C allele warrants further study for association with AD in larger population samples.
Similar articles
-
APOE and APOC1 promoter polymorphisms and the risk of Alzheimer disease in African American and Caribbean Hispanic individuals.Arch Neurol. 2004 Sep;61(9):1434-9. doi: 10.1001/archneur.61.9.1434. Arch Neurol. 2004. PMID: 15364690
-
Promoter polymorphisms which modulate APP expression may increase susceptibility to Alzheimer's disease.Neurobiol Aging. 2008 Feb;29(2):194-202. doi: 10.1016/j.neurobiolaging.2006.10.001. Epub 2006 Nov 16. Neurobiol Aging. 2008. PMID: 17112637
-
Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease.Arch Neurol. 2006 Aug;63(8):1165-9. doi: 10.1001/archneur.63.8.1165. Arch Neurol. 2006. PMID: 16908746
-
Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe.Exp Gerontol. 2004 Oct;39(10):1567-73. doi: 10.1016/j.exger.2004.07.006. Exp Gerontol. 2004. PMID: 15501028 Review.
-
Functional characterization of amyloid beta precursor protein regulatory elements: rationale for the identification of genetic polymorphism.Ann N Y Acad Sci. 2004 Dec;1030:282-8. doi: 10.1196/annals.1329.035. Ann N Y Acad Sci. 2004. PMID: 15659808 Review.
Cited by
-
Deep vein thrombosis inhibitor may play a therapeutic role in post-stroke patients.BMC Med Genet. 2020 Oct 22;21(Suppl 1):174. doi: 10.1186/s12881-020-01108-9. BMC Med Genet. 2020. PMID: 33092540 Free PMC article.
-
Genetic susceptibility for Alzheimer disease neuritic plaque pathology.JAMA Neurol. 2013 Sep 1;70(9):1150-7. doi: 10.1001/jamaneurol.2013.2815. JAMA Neurol. 2013. PMID: 23836404 Free PMC article.
-
A Rare Variation in the 3' Untranslated Region of the Presenilin 2 Gene Is Linked to Alzheimer's Disease.Mol Neurobiol. 2021 Sep;58(9):4337-4347. doi: 10.1007/s12035-021-02429-3. Epub 2021 May 19. Mol Neurobiol. 2021. PMID: 34009547
-
Role of common and rare APP DNA sequence variants in Alzheimer disease.Neurology. 2012 Apr 17;78(16):1250-7. doi: 10.1212/WNL.0b013e3182515972. Epub 2012 Apr 4. Neurology. 2012. PMID: 22491860 Free PMC article.
-
Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis.Biochem Pharmacol. 2014 Apr 15;88(4):486-94. doi: 10.1016/j.bcp.2014.01.032. Epub 2014 Feb 7. Biochem Pharmacol. 2014. PMID: 24513321 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources